Chongqing Fuan Pharmaceutical (Group) Co. Ltd. has prepared and tested class of 7-((5-membered heterocyclic)methyl)-8-carboxylic acid-benzo cyclic borate derivatives reported to be useful for the treatment of bacterial infections.
Chengdu Easton Biopharmaceuticals Co. Ltd. has identified cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Cgenetech (Suzhou, China) Co. Ltd. has synthesized tyrosine-protein kinase JAK2 inhibitors reported to be useful for the treatment of autoimmune diseases, myeloproliferative diseases and graft-versus-host disease.
Pharward Biotechnology Inc. Pte Ltd. has disclosed compounds acting as E3 ubiquitin-protein ligase SIAH1 modulators reported to be useful for the treatment of cocaine dependence.
In what represents its first patenting, Copenhagen, Denmark-based HEI Therapeutics ApS reported seeking patent protection for a point-of-care or home monitoring solution, which enables personalized treatment for hypothyroidism.
Inventors affiliated with Nirsense LLC, are designing somatic and cerebral oximetry devices using functional near-infrared spectroscopy (fNIRS). They have filed for patent protection of wearable systems capable of detecting both optical and non-optical biometric properties of a user to determine their cognitive state.
Institute of Cancer Research UK has described lysyl oxidase homolog 2 (LOXL2) inhibitors reported to be useful for the treatment of cancer and fibrosis.
Bioversys AG has divulged compounds with the ability to interact with accessory gene regulator A (AgrA) and inhibit the expression of AgrA-regulated virulence factors.
Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase ligand binding moiety covalently linked to an histone deacetylase 6 (HDAC6)/8 (HDAC8)-targeting moiety through a linker.
RSS
